HeartBeam Reports Q1 2026 Results, Advances Commercial Launch of Cardiac Monitoring Platform

HeartBeam (NASDAQ: BEAT) announced its first-quarter 2026 financial results on May 14, highlighting the launch of initial commercial partnerships in key U.S. markets and progress in its heart attack detection and ambulatory ECG patch initiatives. The company also completed an April public offering that raised $11.5 million in gross proceeds, providing capital to support its commercial rollout.

The Los Angeles-based medical technology company reported a net loss of $4.7 million for the quarter, improving from a $5.5 million loss in the same period last year. Research and development expenses declined year over year as the company shifted focus toward commercialization of its FDA-cleared cardiac monitoring platform.

HeartBeam’s platform is built on proprietary 3D ECG technology, which the company describes as the first cable-free device capable of collecting ECG signals from three non-coplanar directions and synthesizing them into a standard 12-lead ECG. The system received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology.

The significance of HeartBeam’s platform lies in its potential to enable physicians to identify cardiac health trends and acute conditions without requiring patients to be in a medical facility. By delivering actionable heart intelligence through portable devices, the technology aims to redefine cardiac health management by directing patients to appropriate care based on real-time data.

“We are creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG,” the company stated in its release. “This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.”

The company’s forward-looking statements caution that actual results may differ materially due to risks and uncertainties outlined in its SEC filings, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

For more details, the full press release is available at https://ibn.fm/guMCF. The latest news and updates relating to BEAT can be found in the company’s newsroom at https://ibn.fm/BEAT.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is HeartBeam Reports Q1 2026 Results, Advances Commercial Launch of Cardiac Monitoring Platform.

The post HeartBeam Reports Q1 2026 Results, Advances Commercial Launch of Cardiac Monitoring Platform appeared first on citybuzz.